News

FIRST BIOSIMILAR BREAST CANCER MEDICATION FROM ABDİ İBRAHİM

FIRST BIOSIMILAR BREAST CANCER MEDICATION WILL CONTRIBUTE TRY 130 MILLION ANNUALLY TO THE CAPITAL BUDGET

Abdi İbrahim, the leader of the Turkish pharmaceutical industry, released the first biosimilar with Trastuzumab as the active ingredient that is used for the treatment of breast cancer, which is frequent in women. The medication is under reimbursement coverage by the Ministry of Health, and it will contribute TRY 130 million in one year to the capital budget. It prevents the growth of tumorous mass in breast cancer patients, and will be the first biosimilar monoclonal antibody to be used by medical oncology.

Leading the pioneering biotechnology investments, Abdi İbrahim released the first biosimilar with Trastuzumab as the active ingredient in Turkey. The medication is a biosimilar monoclonal antibody to be used by medical oncology, and it prevents the growth of the tumorous mass in breast cancer patients, providing a treatment opportunity. 

The medication is under reimbursement coverage by the Ministry of Health, and it is expected to contribute TRY 130 million in one year to the capital budget.

It extends lifespan by preventing tumor growth

Breast cancer is one of the most frequent cancers in women, both in the world and in Turkey. Each year 22,000 people are diagnosed with breast cancer around the world. This number increases each year in Turkey. The increase in the number of patients brings on the acceleration of scientific studies conducted on the subject as well.

Conducting studies in the field of breast cancer to extend the lifespan of patients and improve their quality of life, Abdi İbrahim presents an effective treatment for breast cancer through a biosimilar with Trastuzumab as the active ingredient. The medication inhibits the growth of the tumor in HER2 positive patients with the Trastuzumab molecule, thereby extending the lifespan of the patients. Under reimbursement coverage, this medication will be able to be used widely in treatments as it provides an alternative by being accessible by the patients.

SITE MAP
INFORMATION SOCIETY SERVICES
© 2016-2018 Abdi İbrahim İlaç Sanayi ve Tic A.Ş.
The information provided on this site is not intended as an advice. Information provided should be discussed with your healthcare professional.
Phone: 0212 366 8400
E-Mail: info@abdiibrahim.com.tr